Prosidion's future up in the air as Astellas begins assessing options
This article was originally published in Scrip
Executive Summary
Astellas has begun considering strategic options for the future of its UK R&D subsidiary Prosidion, which it acquired last year as part of the purchase of OSI Pharmaceuticals but now apparently considers surplus to its core interests.
You may also be interested in...
Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports